Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Calgary

$17,500.00

Modeling Latent Gene Cooperativity in Viral Tumourigenesis

FY 2018-19

Summary
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiological agent of the most common malignancy in untreated AIDS patients: Kaposi’s sarcoma (KS). The cancer is characterized by large purple skin lesions composed mainly of infected endothelial cells (ECs) that rapidly proliferate, elongate (spindle), and release inflammatory factors. While KSHV has both a latent (minimal gene expression) and a lytic (full genome replication with infectious virion production) phase, KS lesions are composed predominantly of latently infected cells. During latency only six protein products are expressed, underscoring their significance to both tumourigenesis and the EC reprogramming phenotypes described above. Previous work has shown that two of these proteins, KapB (kaposin B) and vFLIP (Fas-associated death domain-like interleukin-1?-converting enzyme-inhibitory protein), are critical to the spindling and inflammatory gene expression phenotypes in virus infected ECs. However, previous studies linking KapB and vFLIP to these phenotypes were heavily reliant on ectopic expression models and the mechanism behind vFLIP induced EC remodeling remains mostly obscure. Therefore, the role of these proteins in tumourigenesis remains largely unexplored. Due to their redundancy, I hypothesize that KapB and vFLIP may be acting cooperatively to maintain the KSHV tumour environment. To investigate this, I will generate KSHV recombinants lacking KapB, vFLIP or the combination and test how these mutant viruses behave with respect to KSHV tumourigenesis phenotypes such as EC reprogramming, viral episome maintenance, processing body loss, and angiogenesis. This work is critical to our understanding of viral oncogenesis and will provide new targets for KS therapy.
Program
Master's Award: Canada Graduate Scholarships
Location
Alberta, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
406469
Name
Kleer Mariel
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Modeling Latent Gene Cooperativity in Viral Tumourigenesis
Programtype2
Studentship Programs
Orgnameinp2
University of Calgary
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Kaposi'S Sarcoma; Latency; Virus
Abstract
Kaposi’s sarcoma-associated herpesvirus (KSHV) is the etiological agent of the most common malignancy in untreated AIDS patients: Kaposi’s sarcoma (KS). The cancer is characterized by large purple skin lesions composed mainly of infected endothelial cells (ECs) that rapidly proliferate, elongate (spindle), and release inflammatory factors. While KSHV has both a latent (minimal gene expression) and a lytic (full genome replication with infectious virion production) phase, KS lesions are composed predominantly of latently infected cells. During latency only six protein products are expressed, underscoring their significance to both tumourigenesis and the EC reprogramming phenotypes described above. Previous work has shown that two of these proteins, KapB (kaposin B) and vFLIP (Fas-associated death domain-like interleukin-1?-converting enzyme-inhibitory protein), are critical to the spindling and inflammatory gene expression phenotypes in virus infected ECs. However, previous studies linking KapB and vFLIP to these phenotypes were heavily reliant on ectopic expression models and the mechanism behind vFLIP induced EC remodeling remains mostly obscure. Therefore, the role of these proteins in tumourigenesis remains largely unexplored. Due to their redundancy, I hypothesize that KapB and vFLIP may be acting cooperatively to maintain the KSHV tumour environment. To investigate this, I will generate KSHV recombinants lacking KapB, vFLIP or the combination and test how these mutant viruses behave with respect to KSHV tumourigenesis phenotypes such as EC reprogramming, viral episome maintenance, processing body loss, and angiogenesis. This work is critical to our understanding of viral oncogenesis and will provide new targets for KS therapy.
Competitiondate
201812
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kleer, Mariel
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~